Labcorp announces expansion of precision oncology portfolio to support pharmaceutical, biopharma, and clinical research in advancing drug development programs

Portfolio expansion solidifies company's commitment to advancing cancer research and patient care burlington, n.c. , april 8, 2024 /prnewswire/ -- labcorp (nyse: lh), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advancing cancer research and patient care on a global scale.
LH Ratings Summary
LH Quant Ranking